Physician profile
Anna S Evans
NPI 1760847842
$6,123.77
in general payments reported to CMS, 2019-2025
23 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $997 · 2023: $794 · 2024: $1,869 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,036 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,036.44 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,656.02 | 2021-2025 | Aveir, Ensite, Accent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,251.23 | 2021-2025 | Lifevest |
| Amgen INC. | $729.63 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $576.80 | 2021-2025 | |
| Boston Scientific Corporation | $500.00 | 2021-2025 | Watchman Flx, Rhythmia Mapping System, General - Therapies |
| Astrazeneca Pharmaceuticals Lp | $258.23 | 2021-2025 | Farxiga, Lokelma, Andexxa |
| Edwards Lifesciences Corporation | $176.00 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.33 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $114.44 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $88.46 | 2022-2025 | |
| Chiesi USA, INC. | $87.03 | 2021-2024 | Kengreal |
| Janssen Pharmaceuticals, INC | $82.51 | 2021-2024 | Xarelto |
| United Orthopedics LLC | $68.13 | 2024 | |
| Novo Nordisk INC | $54.25 | 2021-2024 | Ozempic |
| Merck Sharp & Dohme LLC | $53.50 | 2021-2024 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $49.15 | 2023-2025 | Barostim Neo System |
| Atricure, INC. | $46.76 | 2022 | |
| Abiomed | $42.97 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $42.92 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $41.41 | 2021-2023 | Uptravi, Opsumit |
| Bridgebio Pharma, INC. | $32.67 | 2025 | Attruby |
| Teleflex LLC | $27.31 | 2023 | Urolift |
| Lexicon Pharmaceuticals, INC. | $20.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.